Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
AstraZeneca
Biotech
AstraZeneca drops lead TCR therapy from $200M Neogene buy
AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell therapy clearout.
James Waldron
Jul 29, 2025 4:13am
BMS names AZ's Cristian Massacesi as new chief medical officer
Jul 25, 2025 9:26am
AstraZeneca's blockbuster contender hits phase 3 gMG goals
Jul 24, 2025 6:20am
Fierce Pharma
AZ reveals plan for huge site in Virginia, part of $50B US outlay
Jul 22, 2025 7:45am
AstraZeneca amyloidosis drug fails to reduce mortality in ph. 3
Jul 16, 2025 4:28am
AstraZeneca’s $1.3B hypertension med bet pays off with ph. 3 win
Jul 14, 2025 4:09am
